Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 18/20 | 1.00 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutemetamol F 18 SCHEMBL30668500 | 1.00 | APP (1.00) | APPSULT1A1MAPT | |
| Flutemetamol F 18 SCHEMBL29363499 | 1.00 | APP (1.00) | APPSULT1A1MAPT | |
| Flutemetamol F 18 SCHEMBL10032147 | 1.00 | APP (1.00) | APPSULT1A1MAPT | |
| SCHEMBL5958763 | 0.87 | APP (0.77) | APPSULT1A1MAPT | |
| SCHEMBL14788828 | 0.86 | APP (0.75) | APPSULT1A1MAPT | |
| SCHEMBL15604181 | 0.86 | APP (0.75) | APPMAPT | |
| SCHEMBL13167852 | 0.85 | APP (0.73) | APPSULT1A1MAPT | |
| SCHEMBL2061295 | 0.85 | APP (1.00) | APPSULT1A1MAPT | |
| SCHEMBL12227066 | 0.85 | APP (1.00) | APPSULT1A1MAPT | |
| SCHEMBL13806265 | 0.84 | APP (0.73) | APPSULT1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250147049-A1 | METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER'S DISEASE, AND USE THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-05-08 | — | — | US | claimed |
| US-12186114-B2 | Deep residual inception encoder-decoder network for amyloid PET harmonization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-01-07 | — | — | US | claimed |
| US-20240366808-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE HEALTHCARE LIMITED (GB) | 2024-11-07 | — | — | US | claimed |
| US-20240350683-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | GE HEALTHCARE LIMITED (GB) | 2024-10-24 | — | — | US | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2024-09-12 | — | — | US | claimed |
| US-20240285244-A1 | DEEP RESIDUAL INCEPTION ENCODER-DECODER NETWORK FOR AMYLOID PET HARMONIZATION | BANNER HEALTH | 2024-08-29 | — | — | US | claimed |
| EP-4392067-A1 | METHODS OF TREATING TAU PATHOLOGIES | GENENTECH, INC. (US) | 2024-07-03 | — | — | EP | claimed |
| EP-4139269-A1 | BIOACTIVE PHENOLATE IONIC COMPLEXES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2023-03-01 | — | — | EP | claimed |
| WO-2023275617-A2 | DIAGNOSTIC AND TREATMENT MONITORING BASED ON BLOOD-BRAIN BARRIER DISRUPTION | INSIGHTEC, LTD. (IL) | 2023-01-05 | — | — | WO | claimed |
| US-20220409752-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE HEALTHCARE LIMITED (GB) | 2022-12-29 | — | — | US | claimed |
| WO-2022263594-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE HEALTHCARE LIMITED (GB) | 2022-12-22 | — | — | WO | claimed |
| WO-2022263592-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | GE HEALTHCARE LIMITED (GB) | 2022-12-22 | — | — | WO | claimed |
| EP-4048323-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE Healthcare Limited (GB) | 2022-08-31 | — | — | EP | claimed |
| WO-2022159766-A1 | METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER DISEASE, AND USE THEREOF | WASHINGTON UNIVERSITY (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022120378-A1 | METHOD FOR DIAGNOSING AMYLOID DISEASES | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-06-09 | — | — | WO | claimed |
| CN-114555133-A | Use of cyclodextrins as radiostabilizers | 通用电气健康护理有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022030692-A1 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING PET-CE IMAGE AND APPARATUS THEREOF | 사회복지법인 삼성생명공익재단 | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350683-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | PROC, CYP27B1, TTPA | APP 2544/4885SULT1A1 2699/4885MAPT 1246/4885 |
| US-20220409752-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | SLC7A11, TBCA, GYPA | APP 1295/4885SULT1A1 2450/4885MAPT 431/4885 |
| US-20240366808-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | AQP1, AQP3, TMEM14C | APP 1835/4885SULT1A1 1356/4885MAPT 1720/4885 |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | APP 2732/4885SULT1A1 3614/4885MAPT 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.